HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer
NCT04188951
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Head and Neck Neoplasms
Interventions
DRUG:
Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Sponsor
Henry Ford Health System